Navigation Links
Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
Date:8/28/2008

SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the Company will be presenting at the following upcoming investor conferences:

BioCentury Newsmakers in the Biotech Industry

Thursday, September 4, 2008, 10:00 AM Eastern time

Millennium Broadway Hotel, New York

UBS Global Life Sciences Conference

Tuesday, September 23, 2008, 9:30 AM Eastern time

Grand Hyatt Hotel, New York

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
2. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
3. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
4. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
5. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
6. Cell Therapeutics, Inc. Announces Reverse Stock Split
7. Pixel Bridge Works With Anika Therapeutics to Launch New Website
8. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
9. Arno Therapeutics Announces Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a ... designed, tuned and optimized exclusively for Okuma CNC machining centers at The International ... a collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics ...
(Date:6/22/2016)... June 22, 2016  According to Kalorama Information, ... sequencing (NGS) market include significant efforts in automation ... More accessible and affordable sequencers, say the healthcare ... for consumables including sample prep materials.  The healthcare ... Sample Preparation for Next Generation Sequencing (NGS) , ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
Breaking Biology News(10 mins):